drugset / Trial / NCT00081380

Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00081380

Phase 3 Completed 710 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar I Disorder. The study consists of enrollment and 2 phases, the Open-label treatment Phase and the Randomized treatment Phase. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Timeline

Start
2004-03
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 400 mg
Subject Quetiapine Small molecule 800 mg
Background Divalproex Sodium Small molecule
Background Lithium Unknown

Indications